EAM
MDGL icon

Eventide Asset Management’s Madrigal Pharmaceuticals MDGL Stock Holding History

Eventide Asset Management’s Portfolio MDGL Stock Details MDGL Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$277K Buy
+526
New +$269K ﹤0.01% 266
2018
Q4 		– Sell
-33,000
Closed -$7.07M – 144
2018
Q3 		$7.07M Sell
33,000
-13,000
-28% -$3.26M 0.26% 90
2018
Q2 		$12.9M Buy
46,000
+21,000
+84% +$3.69M 0.53% 66
2018
Q1 		$2.92M Buy
+25,000
New +$3.09M 0.14% 100

Other funds holding MDGL

BBA
Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return
RI
RTW Investments New York $11.7B AUM 174.13% 1-Year Est. Return
JT
Jupiter Topco New York $245B AUM
ACA
Avoro Capital Advisors New York $11.1B AUM 207.82% 1-Year Est. Return
PC
Paulson & Co New York $2.58B AUM 68.51% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Eventide Asset Management's MDGL Position: Q2 2026 in Review

Eventide Asset Management opened a new position in Madrigal Pharmaceuticals (MDGL) in Q2 2026: 526 shares worth $277K. The stake represents ﹤0.01% of the portfolio and ranks #266 among its holdings. This is a return to the name: Eventide Asset Management previously reported a position in MDGL as recently as Q3 2018.

Eventide Asset Management first reported a position in MDGL in Q1 2018 and has held it in 4 quarters since. The position peaked at $12.9M in Q2 2018. 414 funds tracked by Wall St. Rank hold MDGL as of Q2 2026.

  • Eventide Asset Management held 526 shares of Madrigal Pharmaceuticals worth $277K as of Q2 2026.
  • Madrigal Pharmaceuticals was a new Eventide Asset Management position in Q2 2026.
  • Madrigal Pharmaceuticals made up ﹤0.01% of Eventide Asset Management's portfolio in Q2 2026, its #266 holding.
  • Eventide Asset Management first reported a position in Madrigal Pharmaceuticals in Q1 2018 and has held it in 4 quarters since.
  • Eventide Asset Management's Madrigal Pharmaceuticals position peaked at $12.9M in Q2 2018.
  • 414 funds tracked by Wall St. Rank held Madrigal Pharmaceuticals as of Q2 2026.

Based on Eventide Asset Management's 13F filing for Q2 2026, filed 14 Aug 2026.